Jean-Yves Blay, MD, discusses treatment considerations in patients with soft tissue sarcomas.
Jean-Yves Blay, MD, PhD
Advertisement
Articles by Jean-Yves Blay, MD, PhD
Jean-Yves Blay, MD, discusses current treatment challenges in soft tissue sarcomas.
Jean-Yves Blay, MD, discusses the exploration of BI 907828 in patients with sarcoma.
Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the treatment landscape of sarcoma.
Jean-Yves Blay, MD, PhD, professor of Medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the heterogeneity of soft tissue sarcoma.
Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.
Advertisement
Latest Updated Articles
Dr. Blay on the Exploration of BI 907828 in Patients With SarcomaPublished: April 25th 2022 | Updated:
Dr. Jean-Yves Blay on Eribulin in LeiomyosarcomaPublished: October 18th 2016 | Updated:
Dr. Blay on the Heterogeneity of Soft Tissue SarcomaPublished: February 7th 2017 | Updated:
Dr. Blay Discusses the Treatment Landscape of SarcomaPublished: March 21st 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5